MediaMedic

ASH China Voice | Professors Lu Peihua / Zhang Xian: CD7 CAR-T Therapy Significantly Improves Outcomes in R/R CD7-Positive Hematologic Malignancies

By Peter W. PENG 2025.12.18

At the 67th Annual Meeting of the American Society of Hematology (ASH), Professor Lu Peihua and Professor Zhang Xian from Lu Daopei Hospital presented a large-scale clinical study of a…

ASH Hot Topics | Prof. Yang Linhua: Anti-BAFF-R mAb Advances ITP from Symptom Control to Disease Modification

By Mourabit Halima 2025.12.17

Immune thrombocytopenia (ITP) is an immune-mediated thrombocytopenic disorder that can lead to severe bleeding and markedly impair quality of life. At the 67th Annual Meeting of the American Society of…

ASH Guideline Interpretation | Professor Duan Minghui: Key Highlights of the Myelofibrosis Clinical Practice Guidelines and Implications for China

By Mourabit Halima 2025.12.17

On December 6 (local time), a highly anticipated special session on the ASH Clinical Practice Guidelines on Myelofibrosis was successfully held during the American Society of Hematology (ASH) Annual Meeting.…

ASH China Voices | Professors Lu Peihua, Yang Junfang, and He Jiujiang: Advances in CNS-Involved R/R T-ALL/LBL and NUP214::ABL1 Leukemia

By Peng Longmei 2025.12.17

From December 6 to 9, 2025, the 67th Annual Meeting of the American Society of Hematology (ASH) was held in Orlando, USA. As the world’s largest and most influential international…

ASH China Voice | Professor Huang Haiwen: Clinical Value of CAR-T–Transplant Sequencing and the Pola-AR2 Regimen

By Mourabit Halima 2025.12.17

At this year’s Annual Meeting of the American Society of Hematology (ASH), the team led by Professor Huang Haiwen from the First Affiliated Hospital of Soochow University reported multiple important…

ASH China Voice | Professor Chengcheng Fu’s Team: Innovative Therapies and MRD-Driven Strategies Advance Clinical Progress in Multiple Myeloma

By Peter W. PENG 2025.12.16

From December 6 to 9, 2025, the 67th Annual Meeting of the American Society of Hematology (ASH) was held in Orlando, bringing together the latest global research and clinical advances…

ASH Voices from China丨Deyan Liu & Xiaohong Liu: Real-World HSCT Outcomes in 82 Patients with SIL::TAL1-Positive T-ALL/LBL

By Peng Longmei 2025.12.16

From December 6 to 9, 2025, the 67th Annual Meeting of the American Society of Hematology (ASH) was held in Orlando, USA. As the largest and most influential international congress…

ASH Hot Take | Prof. Huaqian Wang: A New Perspective on Low-Risk MDS – Clinical Value of Shortened Hypomethylating Therapy

By Mourabit Halima 2025.12.16

Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic disorders characterized by marked heterogeneity and complex prognosis. While treatment of intermediate- and high-risk disease remains challenging, there is also considerable…

ICIC 2025丨Xiaowen Tang, MD, PhD: VA Plus Modified BuCy Conditioning Advances Transplant Outcomes in High-Risk ALL

By Mourabit Halima 2025.12.15

To promote innovation in China’s cell and immunotherapy fields, deepen scientific exchange, and accelerate translation through global collaboration, the 2025 International Cell & Immunotherapy Conference (CTI 2025) was held on…

TROPION-Breast02 Insights: Redefining First-Line Therapy for Advanced Triple-Negative Breast Cancer

By Mourabit Halima 2025.12.15

At the recently concluded European Society for Medical Oncology Asia Congress (ESMO Asia), participating experts shared and reviewed the latest advances in numerous breast cancer clinical studies. Oncology Frontier has…

Cultivating Virtue to Advance Surgery · Upholding the Way in Clinical Excellence | Xuesong Li’s Team Completes the First Fully Intracorporeal Autologous Kidney Transplant Using a Domestic Surgical Robot

Breast Cancer Chronicle · 2025 Professor Shusen Wang: Advances in Endocrine Therapy for HR+/HER2− Advanced Breast Cancer — Approval of Inavolisib-Based Combinations and New Pathways Opened by the evERA BC Study

Breast Cancer Chronicle · 2025 Professor Jin Yang: Breakthroughs from the ASCENT and TROPION Programs Signal the Dawn of Precision Therapy for Advanced Triple-Negative Breast Cancer

Latest Research from Academician Binghe Xu’s Team: Anucleate Red Blood Cells Act as Tumor DNA “Reservoirs,” with Apoptotic Bodies Identified as the Key Couriers

Professor Honghu Zhu: Advances, Evolution, and Future Directions of Hematopoietic Stem Cell Transplantation in Acute Leukemia丨2026 CSCO Academic Conference on Hematologic Malignancies

CASH 2026 Professor Wenbin Qian: Advancing Fourth-Generation CAR-T Therapy—Decoding Long-Term Efficacy, Resistance Mechanisms, and Future Directions

Annual Review Professor Bing Xu: Interpreting New Paradigms and Future Pathways in the Diagnosis and Treatment of Follicular Lymphoma

CASH 2026 Professor Jun Shi: New Insights into the Immune Mechanisms of Aplastic Anemia — Targeting CD38 and the JAK Pathway Shows Promising Therapeutic Potential

CASH 2026 Professor Erlie Jiang: Four Decades of Continuity and Innovation — The “Tianjin Model” Pioneering a New Era in Hematopoietic Stem Cell Transplantation

Lymphoma Roundtable · ASH Special Professor Qingqing Cai: New Advances in Bispecific Antibody Therapy for Relapsed/Refractory Lymphoma

Cultivating Virtue to Advance Surgery · Upholding the Way in Clinical Excellence | Xuesong Li’s Team Completes the First Fully Intracorporeal Autologous Kidney Transplant Using a Domestic Surgical Robot

Breast Cancer Chronicle · 2025 Professor Shusen Wang: Advances in Endocrine Therapy for HR+/HER2− Advanced Breast Cancer — Approval of Inavolisib-Based Combinations and New Pathways Opened by the evERA BC Study

ASH China Voice | Professors Lu Peihua / Zhang Xian: CD7 CAR-T Therapy Significantly Improves Outcomes in R/R CD7-Positive Hematologic Malignancies

ASH Hot Topics | Prof. Yang Linhua: Anti-BAFF-R mAb Advances ITP from Symptom Control to Disease Modification

ASH Guideline Interpretation | Professor Duan Minghui: Key Highlights of the Myelofibrosis Clinical Practice Guidelines and Implications for China

ASH China Voices | Professors Lu Peihua, Yang Junfang, and He Jiujiang: Advances in CNS-Involved R/R T-ALL/LBL and NUP214::ABL1 Leukemia

ASH China Voice | Professor Huang Haiwen: Clinical Value of CAR-T–Transplant Sequencing and the Pola-AR2 Regimen

ASH China Voice | Professor Chengcheng Fu’s Team: Innovative Therapies and MRD-Driven Strategies Advance Clinical Progress in Multiple Myeloma

ASH Voices from China丨Deyan Liu & Xiaohong Liu: Real-World HSCT Outcomes in 82 Patients with SIL::TAL1-Positive T-ALL/LBL

ASH Hot Take | Prof. Huaqian Wang: A New Perspective on Low-Risk MDS – Clinical Value of Shortened Hypomethylating Therapy

ICIC 2025丨Xiaowen Tang, MD, PhD: VA Plus Modified BuCy Conditioning Advances Transplant Outcomes in High-Risk ALL

TROPION-Breast02 Insights: Redefining First-Line Therapy for Advanced Triple-Negative Breast Cancer

Cultivating Virtue to Advance Surgery · Upholding the Way in Clinical Excellence | Xuesong Li’s Team Completes the First Fully Intracorporeal Autologous Kidney Transplant Using a Domestic Surgical Robot

Breast Cancer Chronicle · 2025 Professor Shusen Wang: Advances in Endocrine Therapy for HR+/HER2− Advanced Breast Cancer — Approval of Inavolisib-Based Combinations and New Pathways Opened by the evERA BC Study

Breast Cancer Chronicle · 2025 Professor Jin Yang: Breakthroughs from the ASCENT and TROPION Programs Signal the Dawn of Precision Therapy for Advanced Triple-Negative Breast Cancer

Latest Research from Academician Binghe Xu’s Team: Anucleate Red Blood Cells Act as Tumor DNA “Reservoirs,” with Apoptotic Bodies Identified as the Key Couriers

Welcome to Mediamedic 👋
It’s nice to meet you.

Welcome to Mediamedic 👋It’s nice to meet you.

Welcome to Mediamedic 👋
It’s nice to meet you.